Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
Dimesna by Lantern Pharma for Non-Small Cell Lung Cancer: Likelihood of Approval
Dimesna is under clinical development by Lantern Pharma and currently in Phase II for Non-Small Cell Lung Cancer. According to...